China SXT Pharmaceuticals, Inc. Cost of Revenue
China SXT Pharmaceuticals, Inc. (SXTC) reported Cost of Revenue of $889.35 thousand for the 12-month period ending 2026-03-31, per its 20-F filed 2026-07-01.
Financial Statements › Expense Statement › Cost of Sales
us-gaap:CostOfRevenue · last filed 2026-07-01
| Period end | Cost of Revenue 6 month | Cost of Revenue 12 month |
|---|---|---|
| 2026-03-31 | $889.35K 20-F · filed 2026-07-01 | |
| 2025-09-30 | $524.85K 6-K · filed 2025-12-31 | |
| 2025-03-31 | $1.37M 20-F · filed 2026-07-01 | |
| 2024-09-30 | $694.74K 6-K · filed 2025-12-31 | |
| 2024-03-31 | $1.37M 20-F · filed 2026-07-01 | |
| 2023-09-30 | $651.24K 6-K · filed 2025-03-28 | |
| 2023-03-31 | $1.55M 20-F · filed 2025-07-31 | |
| 2022-09-30 | $1.12M 6-K · filed 2024-04-05 | |
| 2022-03-31 | $1.35M 20-F · filed 2024-08-13 | |
| 2021-09-30 | $703.72K 6-K · filed 2023-02-24 | |
| 2021-03-31 | $1.94M 20-F · filed 2023-07-31 | |
| 2020-09-30 | $1.04M 6-K · filed 2022-01-14 | |
| 2020-03-31 | $2.46M 20-F/A · filed 2023-05-19 | |
| 2019-09-30 | $1.38M 6-K · filed 2021-01-28 | |
| 2019-03-31 | $2.40M 20-F · filed 2021-08-13 | |
| 2018-09-30 | $1.24M 6-K/A · filed 2020-05-22 | |
| 2018-03-31 | $3.62M 20-F · filed 2020-07-31 | |
| 2017-03-31 | $2.57M 20-F · filed 2019-08-15 |